Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models.

Zhanfang Guo Jingqin R Luo R Jay Mashl Jeremy Hoog Piyush Maiti Nicole Fettig Sherri R Davies Rebecca Aft Jason M Held Ramaswamy Govindan Li Ding Shunqiang Li Cornelius von Morze Gerburg M Wulf Kooresh I Shoghi Cynthia X Ma

Published in: Cancer research communications (2024)

In this research, we demonstrated that the pan-PI3K inhibitor copanlisib enhanced the cytotoxicity of eribulin in a panel of TNBC PDX models. The improved tumor growth inhibition was irrespective of PI3K pathway alteration and was corroborated by the enhanced mitotic arrest and apoptotic induction observed in PDX tumors after combination therapy compared with each drug alone. These data provide the preclinical rationale for the clinical testing in TNBC.

Keyphrases

combination therapy
metastatic breast cancer
cell cycle
cell death
phase ii
clinical trial
electronic health record
cell therapy
open label
adverse drug
study protocol